Paul Anderson was interviewed by Alan Kohler. There was fartoo much to post in full, and most of it is already known, so I have extracted somehighlights.
Hope its not to repetative for you all.
Talking about the BH deal: “We maintain ownership of theintellectual property."
PA described the collagen medical devic e product, which is sold directly to dental doctors for $300 to $500 AUD sold in Australia & globally.
In response to the question of how much OCC gets, PS stated "commercial in confidence", and "was happy with the arrangements".
Also: “80% of dental market is covered by top 5 companies, of whichBH is one. It is distributed by BH & its family of companies.”
“We are looking forward to the Aust & European productlaunch, probably Q2 this year.”
He talked about Remplir, nothing new mentioned; gave some history ofthe company, repairing tendons, driving towards aust approval for regenerationof human tendon tissue.
Regarding IP:
“I’m very proud of what we’ve done in thiscompany with intellectual property, we have over 80 pieces of IP approvedacross the globe, with a total of about 120 in play with all the differentjurisdictions. We have a family of five patents and they sit around themanufacture of our collagen membrane”
Regarding competition:
“we are at the very forefront of thistechnology and that it’s not just the IP, it’s also about your clinical acumen,it’s about how you engage with surgeons and about how you can drive thistechnology forward.”
Regarding the future:
“we certainly could be cash positive inthree to five years in combination of our dental and nerve product. What Iwould say also, though, is that we have a tremendously exciting pipeline ofproducts as well and our company is currently developing what’s called a, inworking title, a collagen-based rope or smart graft. What that’s doing, isturning our collagen sheets into collagen ropes that can be used for ligamentand tendon replacement. That in itself is a gangbuster concept, it’s agangbuster idea and it’s a tremendous product in its own right. And so, we’regoing to continue to develop our R&D portfolio, we’re going to continue todevelop our prototypes leading towards these really unique collagen basedmedical device and cellular therapy approaches. Our work is not done, we’rereally excited about what we have in the market today and what that’s doing forour company, but we’re equally excited about what we have in the pipelinecoming down the line.”
When queried with “What I hear from that, is you could becash positive in three to five years, but you probably won’t be because you’llbe investing some more?”
PA responded: “I think so, I mean I think that’s the sound –these opportunities are just too big for us to ignore, they’re really, reallyexciting and most importantly, this is not just us getting excited about theseopportunities, these are surgeons giving us feedback saying, if you can bring aproduct like that to market, that’s a game changer for our practice. When youhear those types of things, that gives me, as a translational developer oftechnologies, a lot of excitement about the next big opportunities to come downthe pipeline in this company.”
In response to the question: “I suppose you could be cashpositive by selling more licences?”,
PA responded “Well, that’s right and we’vegot a great model there, we know our value, I can tell you the nerve producthas got greater value. The average sales price for the nerve product is around$1,500 per procedure, as opposed to 300 and 500. So, there’s a big differencein our model. The nerve is a lower volume, higher value product, the dentalproduct are higher volume, lower value, and so there’s some strategy in that aswell, Alan, around how we’ve developed our technologies and so we’re reallyexcited about this next phase with our nerve repair, not just in Australia, butalso driving that into the US with the partners like Washington University andDrs Dy and Brogan.”
(20min delay)